Summary
This 8-K filing by Abbott Laboratories (ABT) announces the successful completion of its acquisition of Alere Inc. on October 3, 2017. The transaction, initially announced in January 2016, was finalized through a merger where Alere became a subsidiary of Abbott. Each Alere shareholder received $51.00 in cash per share, and outstanding Alere stock options and restricted stock units were settled in cash as well. This strategic acquisition significantly expands Abbott's diagnostics business, a key growth area for the company. The filing also details the financing for this approximately $4.6 billion acquisition. Abbott secured $2.8 billion through a Term Loan Agreement and an additional $1.7 billion via its Revolving Credit Agreement. This indicates a substantial increase in debt to fund the acquisition, which investors should consider when evaluating the company's leverage and financial flexibility going forward. The completion of this deal marks a significant milestone for Abbott, aiming to enhance its market position in the diagnostics sector.
Key Highlights
- 1Abbott Laboratories has successfully completed the acquisition of Alere Inc. as of October 3, 2017.
- 2The acquisition was effected through a merger, with Alere becoming a subsidiary of Abbott.
- 3Alere shareholders received $51.00 in cash per share, totaling approximately $4.5 billion for outstanding shares.
- 4Outstanding Alere stock options and restricted stock units were also settled in cash, amounting to approximately $100 million.
- 5The total aggregate consideration paid for the acquisition was approximately $4.6 billion, excluding transaction fees.
- 6Abbott financed the acquisition through a $2.8 billion Term Loan Agreement and a $1.7 billion borrowing under its Revolving Credit Agreement.
- 7The acquisition is expected to bolster Abbott's presence and capabilities in the diagnostics market.